With the market steadily pushing above and beyond its all-time highs, it’s becoming increasingly difficult to find stocks with compelling valuations. With this in mind, we asked three of our contributors which stocks they think are still bargains that might be worth buying right now.
Category: Gilead Sciences
Gilead Executive Says Pharmacy Benefit Managers Keep Prices High
Gilead Sciences Inc.’s hepatitis C cure set off a firestorm of criticism over high drug prices in 2014 that hasn’t let up since. Now an executive says the company can’t cut the product’s price because middlemen who manage drug benefits would refuse to cover it.
Is Gilead Sciences Getting Ready for a Massive Acquisition?
Sinking earnings. Horrible outlook for this year. Perhaps the big biotech needs to develop an antidepressant — just to give to its shareholders.
Why Intercept Pharmaceuticals’ Latest News Caused the Stock to Jump
So when the companyannounced on Friday morning that it was making a significant change to its late-stage clinical study of obeticholic acid in treating NASH, investors were eager to find out what’s going on. Intercept’s phase 3 REGENERATE clinical trial initially had two co-primary endpoints: fibrosis improvement with no worsening of NASH and NASH resolution with no worsening of fibrosis.
Gilead’s Biggest Blockbusters Are Fading Fast, Biotech Warns
Gilead Sciences Inc.’s massive hepatitis C franchise is fading, the company warned Tuesday, projecting that sales this year could be just two-thirds of what investors had been expecting. Revenue from the company’s drugs for the viral infection will be $7.5 billion to $9 billion in 2017, Gilead said in a statement.
3 Crucial Questions Gilead Sciences Should Answer Tuesday
It’s the most wonderful time of the quarter. The time when every business cracks open its books and tells us what’s going on.
3 Reasons Gilead Sciences Inc. Stock Could Rise
Here are three things that could get shares turned around. OK, so perhaps anything is a bit extreme.
Should Investors Bet on Gilead Sciences Version 3.0?
CEOMark Pruzanski presented late Wednesday at the J.P. Morgan Healthcare Conference. Pruzanski obviously focused on Intercept’s achievements and plans.
Biotech Stocks: What to Watch in 2017
You probably didn’t like 2016 very much if you owned biotech stocks. Many biotech stocks, including some solid ones, performed dismally.
Will 2017 Be Gilead Sciences Inc.’s Worst Year Yet?
The biotech stock is down over 25% in 2016. Sales for hepatitis C virus drugs Harvoni and Sovaldi are dropping like a brick.
The Most Expensive Drugs of 2016
Prescription drug prices have gotten out of control for many Americans and many insurers. Some drugs cost as much as premium sports cars.